These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2444781)

  • 1. Coronary vascular actions of synthetic atrial natriuretic factor in isolated vascular preparations.
    Yanagisawa A; Osborne JA; Stahl GL; Lefer AM
    J Cardiovasc Pharmacol; 1987 Sep; 10(3):320-6. PubMed ID: 2444781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological actions of synthetic atrial natriuretic factor on coronary vascular smooth muscle.
    Yanagisawa A; Lefer AM
    Jpn Circ J; 1988 Dec; 52(12):1436-40. PubMed ID: 2907351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary vascular and endothelial reactivity changes in transgenic mice overexpressing atrial natriuretic factor.
    Ku DD; Guo L; Dai J; Acuff CG; Steinhelper ME
    Am J Physiol; 1996 Dec; 271(6 Pt 2):H2368-76. PubMed ID: 8997295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive effects of eicosapentaenoic acid on isolated vascular smooth muscle.
    Yanagisawa A; Lefer AM
    Basic Res Cardiol; 1987; 82(2):186-96. PubMed ID: 3038070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of coronary effects of atrial natriuretic factor in dogs.
    Ertl G; Bauer B; Gaudron P; Kolb M; Kochsiek K
    Eur J Clin Invest; 1992 Aug; 22(8):516-22. PubMed ID: 1425857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial natriuretic factor causes specific relaxation of rat renal arcuate arteries.
    Aalkjaer C; Mulvany MJ; Nyborg NC
    Br J Pharmacol; 1985 Oct; 86(2):447-53. PubMed ID: 2932194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial natriuretic factor and cyclic guanosine 3',5'-monophosphate in vascular smooth muscle.
    Sato M; Abe K; Takeuchi K; Yasujima M; Omata K; Hiwatari M; Kasai Y; Tanno M; Kohzuki M; Kudo K
    Hypertension; 1986 Sep; 8(9):762-71. PubMed ID: 3017853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The actions of atrial natriuretic factor on the vascular wall.
    Vlasuk GP; Babilon RW; Nutt RF; Ciccarone TM; Winquist RJ
    Can J Physiol Pharmacol; 1987 Aug; 65(8):1684-9. PubMed ID: 2825943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and vascular effects of atrial natriuretic factor during cardiopulmonary bypass.
    Hynynen M; Palojoki R; Heinonen J; Tikkanen I; Harjula AL; Fyhrquist F
    Chest; 1991 Nov; 100(5):1203-9. PubMed ID: 1834440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial natriuretic factor receptor heterogeneity and stimulation of particulate guanylate cyclase and cyclic GMP accumulation.
    Leitman DC; Murad F
    Endocrinol Metab Clin North Am; 1987 Mar; 16(1):79-105. PubMed ID: 2892671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic GMP release and vasodilatation induced by EDRF and atrial natriuretic factor in the isolated perfused kidney of the rat.
    Burton GA; MacNeil S; de Jonge A; Haylor J
    Br J Pharmacol; 1990 Feb; 99(2):364-8. PubMed ID: 2158376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible mechanisms underlying the vasorelaxant response to atrial natriuretic factor.
    Winquist RJ
    Fed Proc; 1986 Aug; 45(9):2371-5. PubMed ID: 3015691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle.
    Yanagisawa A; Smith JA; Brezinski ME; Lefer AM
    Eur J Pharmacol; 1987 Jan; 133(1):89-96. PubMed ID: 3030773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation and role of guanylate cyclase-cyclic GMP in vascular relaxation.
    Murad F; Waldman S; Molina C; Bennett B; Leitman D
    Prog Clin Biol Res; 1987; 249():65-76. PubMed ID: 2890172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems.
    Wright RS; Wei CM; Kim CH; Kinoshita M; Matsuda Y; Aarhus LL; Burnett JC; Miller WL
    J Am Coll Cardiol; 1996 Oct; 28(4):1031-8. PubMed ID: 8837586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of atrial natriuretic polypeptide and organic nitrates on levels of relaxation and cyclic nucleotide of canine coronary artery with and without endothelial injury.
    Nakagawa H; Okumura K; Hashimoto H; Ito T; Ogawa K; Satake T
    Heart Vessels; 1988; 4(1):19-25. PubMed ID: 2846505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial natriuretic factor (ANF) inhibits arginine vasopressin-stimulated Ca2+ fluxes and cell contraction in vascular smooth muscle cells.
    Meyer-Lehnert H; Tsai P; Schrier RW
    Klin Wochenschr; 1987; 65 Suppl 8():115-21. PubMed ID: 3037182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic actions of a synthetic atrial natriuretic factor.
    Baum T; Sybertz EJ; Watkins RW; Nelson S; Coleman W; Pula KK; Prioli N; Rivelli M; Grossman A
    J Cardiovasc Pharmacol; 1986; 8(5):898-905. PubMed ID: 2429088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial natriuretic factor in the Langendorff perfused coronary vasculature of the rabbit isolated heart.
    Klair SS; Louttit JB; Charlton PA
    Life Sci; 1989; 45(25):2477-83. PubMed ID: 2532696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxic coronary vasodilatation and cGMP overproduction are blocked by a nitric oxide synthase inhibitor, but not by a guanylyl cyclase ANF receptor antagonist.
    Park KH; Levi R
    Eur J Pharmacol; 1994 Apr; 256(1):99-102. PubMed ID: 7517893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.